Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: An exploratory analysis
Open Access
- 30 January 2007
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 56 (2) , 688-692
Abstract
Objective: To evaluate the effectiveness of methotrexate (MTX), which works not only as an immunosuppressant, but also as a potent antiinflammatory agent, as an alternative therapeutic option for patients with severe calcium pyrophosphate deposition disease (CPDD) who fail to respond to standard therapy with nonsteroidal antiinflammatory drugs and/or glucocorticoids.Methods: We analyzed, in 2 university hospitals in Switzerland, consecutive patients with CPDD that was resistant to classic treatment and were subsequently treated with MTX. Before and after initiation of MTX therapy, we quantified the frequency of pseudogout attacks, pain intensity, the number of swollen and tender joints, and inflammatory biomarkers. Clinical and biologic side effects of MTX and patients satisfaction with MTX treatment were also evaluated.Results: The study included 5 patients treated with low dosages of MTX (5–20 mg/week). The mean followup time with MTX was 50.4 months (range 6–81 months). All patients reported an excellent clinical response, with marked improvement within a mean period of 7.4 weeks. A significant decrease in pain intensity (P < 0.0001), swollen and tender joint counts (P < 0.0001), and frequency of attacks was observed. The biomarkers of inflammation decreased markedly when systematically analyzed (3 patients). No significant side effects were reported.Conclusion: This study suggests that MTX could be a valuable therapeutic option for severe CPDD that is refractory to conventional therapy.Keywords
This publication has 12 references indexed in Scilit:
- Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid ArthritisPharmacological Reviews, 2005
- Inflammation and tissue damage in crystal deposition diseasesCurrent Opinion in Rheumatology, 2005
- Genetic studies of chondrocalcinosisCurrent Opinion in Rheumatology, 2005
- Biologic effects of calcium-containing crystalsCurrent Opinion in Rheumatology, 2005
- Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalitiesAnnals of the Rheumatic Diseases, 2005
- Inorganic pyrophosphate (PPI) in pathologic calcification of articular cartilageFrontiers in Bioscience-Landmark, 2005
- Adenosine: an endogenous regulator of innate immunityTrends in Immunology, 2004
- Safety of low dose methotrexate in elderly patients with rheumatoid arthritisPostgraduate Medical Journal, 2000
- The effects of drug therapy on radiographic progression of rheumatoid arthritis. results of a 36‐week randomized trial comparing methotrexate and auranofinArthritis & Rheumatism, 1993
- Calcium Pyrophosphate Dihydrate Crystal Deposition Disease: Nomenclature and Diagnostic CriteriaAnnals of Internal Medicine, 1977